Skip to main content
SpringerLink
Log in

Photoprotection by Nicotinamide

  • Chapter
  • First Online:
Book cover Nutrition for Healthy Skin

  • 2983 Accesses

Abstract

Nicotinamide is the primary precursor of nicotinamide adenine dinucleotide (NAD) [1], which is required for the manufacture of adenosine triphosphate (ATP) in the citric acid cycle (Fig. 11.1). Ultraviolet (UV) irradiation causes both DNA damage and depletion of cellular energy (NAD) [2], which is required for efficient DNA repair. Following UV irradiation, cellular NAD content is an important determinant of cell survival [2]. Human skin cells with reduced levels of NAD have a lower survival rate and higher genomic instability following UV exposure [2], whereas increased intracellular NAD is associated with enhanced protection against photo-oxidative stress [3]. As the precursor of NAD, nicotinamide would be expected to enhance DNA repair in UV-irradiated cells. At low concentrations (less than 3 mM), nicotinamide does enhance repair in UV-irradiated, repair-proficient cell lines, although with higher nicotinamide concentrations (5 mM), DNA repair returned to control levels [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jacobson, E.L., Dame, A.J., Pyrek, J.S., et al.: Evaluating the role of niacin in human carcinogenesis. Biochimie 77, 394–398 (1995)

    Article  CAS  PubMed  Google Scholar 

  2. Jacobson, E.L., Giacomoni, P.U., Roberts, M.J., et al.: Optimizing the energy status of skin cells during solar radiation. J. Photochem. Photobiol. B Biol. 63, 141–147 (2001)

    Article  CAS  Google Scholar 

  3. Wright, S.C., Wei, Q.S., Kinder, D.H., et al.: Biochemical pathways of apoptosis: nicotinamide adenine dinucleotide-deficient cells are resistant to tumor necrosis factor or ultraviolet light activation of the 24-kD apoptotic protease and DNA fragmentation. J. Exp. Med. 183, 463–471 (1996)

    Article  CAS  PubMed  Google Scholar 

  4. Riklis, E., Kor, R., Marko, R.: Trends and developments in radioprotection: the effect of nicotinamide on DNA repair. Int. J. Radiat. Biol. 57, 699–708 (1990)

    Article  CAS  PubMed  Google Scholar 

  5. Berger, N.A.: Poly(ADP-ribose) in the cellular response to DNA damage. Radiat. Res. 101, 4–15 (1985)

    Article  CAS  PubMed  Google Scholar 

  6. de Murcia, J.M., Niedergang, C., Trucco, C., et al.: Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells. Proc. Natl. Acad. Sci. USA 94, 7303–7307 (1997)

    Article  PubMed  Google Scholar 

  7. Chatterjee, S., Cheng, M.F., Berger, N.A.: Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun. 2, 401–407 (1990)

    CAS  PubMed  Google Scholar 

  8. Virag, L., Szabo, C.: The therapeutic potential of poly(ADP-ribose) polymerase inhibitors. Pharmacol. Rev. 54, 375–429 (2002)

    Article  CAS  PubMed  Google Scholar 

  9. Kripke, M.L., Cox, P.A., Alas, L.G., et al.: Pyrimidine dimers in DNA initiate systemic immunosuppression in UV-irradiated mice. Proc. Natl. Acad. Sci. USA 89, 7516–7520 (1992)

    Article  CAS  PubMed  Google Scholar 

  10. Ying, W., Garnier, P., Swanson, R.A.: NAD+ repletion prevents PARP-1-induced glycolytic blockade and cell death in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 308, 809–813 (2003)

    Article  CAS  PubMed  Google Scholar 

  11. Cosmetic Ingredient Review (CIR) Expert Panel. Final report of the safety assessment of niacinamide and niacin. Int. J. Toxicol. 24(Suppl 5), 1–31 (2005)

    Google Scholar 

  12. Drugdex drug evaluations: niacinamide. In: Klasco, R. (ed.) DrugDex(R) System. Thomsom Micromedex, Greenwood Village, Colorado (2006)

    Google Scholar 

  13. Magni, G., Amici, A., Emanuelli, M., et al.: Enzymology of NAD+ homeostasis in man. Cell. Mol. Life Sci. 61, 19–34 (2004)

    Article  CAS  PubMed  Google Scholar 

  14. Morris, M.C., Evans, D.A., Bienias, J.L., et al.: Dietary niacin and the risk of incident Alzheimer’s disease and of cognitive decline. J. Neurol. Neurosurg. Psychiatry 75, 1093–1099 (2004)

    Article  CAS  PubMed  Google Scholar 

  15. Karthikeyan, K., Thappa, D.M.: Pellagra and skin. Int. J. Dermatol. 41, 476–481 (2002)

    Article  PubMed  Google Scholar 

  16. Hegyi, J., Schwartz, R.A., Hegyi, V.: Pellagra: dermatitis, dementia, and diarrhea. Int. J. Dermatol. 43, 1–5 (2004)

    Article  PubMed  Google Scholar 

  17. Murray, M.F.: Tryptophan depletion and HIV infection: a metabolic link to pathogenesis. Lancet Infect. Dis. 3, 644–652 (2003)

    Article  CAS  PubMed  Google Scholar 

  18. Bilu, D., Mamelak, A.J., Nguyen, R.H., et al.: Clinical and epidemiologic characterization of photosensitivity in HIV-positive individuals. Photodermatol. Photoimmunol. Photomed. 20, 175–183 (2004)

    Article  PubMed  Google Scholar 

  19. DiPalma, J.R., Thayer, W.S.: Use of niacin as a drug. Annu. Rev. Nutr. 11, 169–187 (1991)

    Article  CAS  PubMed  Google Scholar 

  20. Petley, A., Macklin, B., Renwick, A.G., et al.: The pharmacokinetics of nicotinamide in humans and rodents. Diabetes 44, 152–155 (1995)

    Article  CAS  PubMed  Google Scholar 

  21. Hoskin, P.J., Stratford, M.R., Saunders, M.I., et al.: Administration of nicotinamide during chart: pharmacokinetics, dose escalation, and clinical toxicity. Int. J. Radiat. Oncol. Biol. Phys. 32, 1111–1119 (1995)

    CAS  PubMed  Google Scholar 

  22. Dragovic, J., Kim, S.H., Brown, S.L., et al.: Nicotinamide pharmacokinetics in patients. Radiother. Oncol. 36, 225–228 (1995)

    Article  CAS  PubMed  Google Scholar 

  23. Stratford, M.R., Rojas, A., Hall, D.W., et al.: Pharmacokinetics of nicotinamide and its effect on blood pressure, pulse and body temperature in normal human volunteers. Radiother. Oncol. 25, 37–42 (1992)

    Article  CAS  PubMed  Google Scholar 

  24. Kaanders, J.H., Stratford, M.R., Liefers, J., et al.: Administration of nicotinamide during a five- to seven-week course of radiotherapy: pharmacokinetics, tolerance, and compliance. Radiother. Oncol. 43, 67–73 (1997)

    Article  CAS  PubMed  Google Scholar 

  25. Yiasemides, E., Sivapirabu, G., Halliday, G.M., et al.: Oral nicotinamide protects against ultraviolet radiation-induced immunosuppression in humans. Carcinogenesis 30, 101–105 (2009)

    Google Scholar 

  26. Knip, M., Douek, I.F., Moore, W.P., et al.: Safety of high-dose nicotinamide: a review. Diabetologia 43, 1337–1345 (2000)

    Article  CAS  PubMed  Google Scholar 

  27. Horsman, M.R., Hoyer, M., Honess, D.J., et al.: Nicotinamide pharmacokinetics in humans and mice: a comparative assessment and the implications for radiotherapy. Radiother. Oncol. 27, 131–139 (1993)

    Article  CAS  PubMed  Google Scholar 

  28. Neumann, R., Rappold, E., Pohl-Markl, H.: Treatment of polymorphous light eruption with nicotinamide: a pilot study. Br. J. Dermatol. 115, 77–80 (1986)

    Article  CAS  PubMed  Google Scholar 

  29. Chaffins, M.L., Collison, D., Fivenson, D.P.: Treatment of pemphigus and linear IgA dermatosis with nicotinamide and tetracycline: a review of 13 cases. J. Am. Acad. Dermatol. 28, 998–1000 (1993)

    Article  CAS  PubMed  Google Scholar 

  30. Bernier, J., Stratford, M.R., Denekamp, J., et al.: Pharmacokinetics of nicotinamide in cancer patients treated with accelerated radiotherapy: the experience of the Co-operative Group of Radiotherapy of the European Organization for Research and Treatment of Cancer. Radiother. Oncol. 48, 123–133 (1998)

    Article  CAS  PubMed  Google Scholar 

  31. Kademian, M., Bechtel, M., Zirwas, M.: Case reports: new onset flushing due to unauthorized substitution of niacin for nicotinamide. J. Drugs Dermatol. 6, 1220–1221 (2007)

    PubMed  Google Scholar 

  32. Kolbach, D.N., Remme, J.J., Bos, W.H., et al.: Bullous pemphigoid successfully controlled by tetracycline and nicotinamide. Br. J. Dermatol. 133, 88–90 (1995)

    Article  CAS  PubMed  Google Scholar 

  33. Fivenson, D.P., Breneman, D.L., Rosen, G.B., et al.: Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch. Dermatol. 130, 753–758 (1994)

    Article  CAS  PubMed  Google Scholar 

  34. Gaudineau, C., Auclair, K.: Inhibition of human P450 enzymes by nicotinic acid and nicotinamide. Biochem. Biophys. Res. Commun. 317, 950–956 (2004)

    Article  CAS  PubMed  Google Scholar 

  35. COLIPA: COLIPA sun protection factor test method. Report No.: 94/289, The European Cosmetic Toiletry and Perfumery Association, Brussells (1994)

    Google Scholar 

  36. Reiche, L., Wojnarowska, F., Mallon, E.: Combination therapy with nicotinamide and tetracyclines for cicatricial pemphigoid: further support for its efficacy. Clin. Exp. Dermatol. 23, 254–257 (1998)

    Article  CAS  PubMed  Google Scholar 

  37. Fivenson, D.P., Kimbrough, T.L.: Lichen planus pemphigoides: combination therapy with tetracycline and nicotinamide. J. Am. Acad. Dermatol. 36, 638–640 (1997)

    Article  CAS  PubMed  Google Scholar 

  38. Berk, M.A., Lorincz, A.L.: The treatment of bullous pemphigoid with tetracycline and niacinamide. A preliminary report. Arch. Dermatol. 122, 670–674 (1986)

    Article  CAS  PubMed  Google Scholar 

  39. Goon, A.T., Tan, S.H., Khoo, L.S., et al.: Tetracycline and nicotinamide for the treatment of bullous pemphigoid: our experience in Singapore. Singapore Med. J. 41, 327–330 (2000)

    CAS  PubMed  Google Scholar 

  40. Chaidemenos, G.C.: Tetracycline and niacinamide in the treatment of blistering skin diseases. Clin. Dermatol. 19, 781–785 (2001)

    Article  CAS  PubMed  Google Scholar 

  41. Burger, D.R., Vandenbark, A.A., Daves, D., et al.: Nicotinamide: suppression of lymphocyte transformation with a component identified in human transfer factor. J. Immunol. 117, 797–801 (1976)

    CAS  PubMed  Google Scholar 

  42. Handfield-Jones, S., Jones, S., Peachey, R.: High dose nicotinamide in the treatment of necrobiosis lipoidica. Br. J. Dermatol. 118, 693–696 (1988)

    Article  CAS  PubMed  Google Scholar 

  43. Shalita, A.R., Smith, J.G., Parish, L.C., et al.: Topical nicotinamide compared with clindamycin gel in the treatment of inflammatory acne vulgaris. Int. J. Dermatol. 34, 434–437 (1995)

    Article  CAS  PubMed  Google Scholar 

  44. Draelos, Z.D., Ertel, K., Berge, C.: Niacinamide-containing facial moisturizer improves skin barrier and benefits subjects with rosacea. Cutis 76, 135–141 (2005)

    PubMed  Google Scholar 

  45. Hakozaki, T., Minwalla, L., Zhuang, J., et al.: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br. J. Dermatol. 147, 20–31 (2002)

    Article  CAS  PubMed  Google Scholar 

  46. Tanno, O., Ota, Y., Kitamura, N., et al.: Nicotinamide increases biosynthesis of ceramides as well as other stratum corneum lipids to improve the epidermal permeability barrier. Br. J. Dermatol. 143, 524–531 (2000)

    Article  CAS  PubMed  Google Scholar 

  47. Soma, Y., Kashima, M., Imaizumi, A., et al.: Moisturizing effects of topical nicotinamide on atopic dry skin. Int. J. Dermatol. 44, 197–202 (2005)

    Article  CAS  PubMed  Google Scholar 

  48. Halliday, G.M., Rana, S.: The effects of solar radiation on the immune response in humans. In: Giacomoni, P.U. (ed.) Biophysical and Physiological Effects of Solar Radiation on Human Skin. The Royal Society for Chemistry, Cambridge pp. 127–163 (2007)

    Google Scholar 

  49. Halliday, G.M.: Inflammation, gene mutation and photoimmunosuppression in response to UVR-induced oxidative damage contributes to photocarcinogenesis. Mutat. Res. 571, 107–120 (2005)

    CAS  PubMed  Google Scholar 

  50. Kuchel, J.M., Barnetson, R.S., Halliday, G.M.: Nitric oxide appears to be a mediator of solar-simulated ultraviolet radiation-induced immunosuppression in humans. J. Invest. Dermatol. 121, 587–593 (2003)

    Article  CAS  PubMed  Google Scholar 

  51. Yuen, K.S., Nearn, M.R., Halliday, G.M.: Nitric oxide-mediated depletion of Langerhans cells from the epidermis may be involved in UVA radiation-induced immunosuppression. Nitric Oxide 6, 313–318 (2002)

    Article  CAS  PubMed  Google Scholar 

  52. Hornig-Do, H.T., von Kleist-Retzow, J.C., KLanz, K., et al.: Human epidermal keratinocytes accumulate superoxide due to low activity of Mn-SOD, leading to mitochondrial functional impairment. J. Invest. Dermatol. 127, 1084–1093 (2007)

    Article  CAS  PubMed  Google Scholar 

  53. Kuchel, J.M., Barnetson, R.S.C., Halliday, G.M.: Cyclobutane pyrimidine dimer formation is a molecular trigger for solar-simulated ultraviolet radiation-induced suppression of memory immunity in humans. Photochem. Photobiol. Sci. 4, 577–582 (2005)

    Article  CAS  PubMed  Google Scholar 

  54. Halliday, G.M.B., Bock, V.L., Moloney, F.J., Lyons, J.G.: SWI/SNF: a chromatin-remodelling complex with a role in carcinogenesis. Int. J. Biochem. Cell. Biol. 41, 725–728

    Google Scholar 

  55. Fousteri, M., Mullenders, L.H.: Transcription-coupled nucleotide excision repair in mammalian cells: molecular mechanisms and biological effects. Cell Res. 18, 73–84 (2008)

    Article  CAS  PubMed  Google Scholar 

  56. Byrne, S.N., Halliday, G.M.: B cells activated in lymph nodes in response to ultraviolet irradiation or by interleukin-10 inhibit dendritic cell induction of immunity. J. Invest. Dermatol. 124, 570–578 (2005)

    Article  CAS  PubMed  Google Scholar 

  57. Rana, S., Byrne, S.N., MacDonald, L.J., et al.: Ultraviolet B suppresses immunity by inhibiting effector and memory T cells. Am. J. Pathol. 172, 993–1004 (2008)

    Article  PubMed  Google Scholar 

  58. Gensler, H.L.: Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr. Cancer 29, 157–162 (1997)

    Article  CAS  PubMed  Google Scholar 

  59. Gensler, H.L., Williams, T., Huang, A.C., et al.: Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr. Cancer 34, 36–41 (1999)

    Article  CAS  PubMed  Google Scholar 

  60. Ludwig, A., Dietel, M., Schafer, G., et al.: Nicotinamide and nicotinamide analogues as antitumor promoters in mouse skin. Cancer Res. 50, 2470–2475 (1990)

    CAS  PubMed  Google Scholar 

  61. Damian, D.L., Halliday, G.M.: Measurement of ultraviolet radiation-induced suppression of recall contact and delayed-type hypersensitivity in humans. Methods 28, 34–45 (2002)

    Article  CAS  PubMed  Google Scholar 

  62. Phan, T.A., Halliday, G.M., Barnetson, R.S., et al.: Spectral and dose dependence of ultraviolet radiation-induced immunosuppression. Front. Biosci. 11, 394–411 (2006)

    Article  CAS  PubMed  Google Scholar 

  63. Halliday, G.M., Bestak, R., Yuen, K.S., et al.: UVA-induced immunosuppression. Mutat. Res. 422, 139–145 (1998)

    CAS  PubMed  Google Scholar 

  64. Damian, D.L., Barnetson, R.S., Halliday, G.M.: Low-dose UVA and UVB have different time courses for suppression of contact hypersensitivity to a recall antigen in humans. J. Invest. Dermatol. 112, 939–944 (1999)

    Article  CAS  PubMed  Google Scholar 

  65. Wolf, P., Hoffmenn, C., Quehenberger, F., et al.: Immune protection factors of chemical sunscreens measured in the local contact hypersensitivity model in humans. J. Invest. Dermatol. 121, 1080–1087 (2003)

    Article  CAS  PubMed  Google Scholar 

  66. Damian, D.L., Barnetson, R.S., Halliday, G.M.: Effects of low-dose ultraviolet radiation on in vivo human cutaneous recall responses. Australas. J. Dermatol. 42, 161–167 (2001)

    Article  CAS  PubMed  Google Scholar 

  67. Gensler, H.L., Williams, T., Huang, A.C., et al.: Oral niacin prevents photocarcinogenesis and photoimmunosuppression in mice. Nutr. Cancer 34, 36–41 (1999)

    Article  CAS  PubMed  Google Scholar 

  68. Gensler, H.L.: Prevention of photoimmunosuppression and photocarcinogenesis by topical nicotinamide. Nutr. Cancer 29, 157–162 (1997)

    Article  CAS  PubMed  Google Scholar 

  69. Damian, D.L., Patterson, C.R.S., Stapelberg, M., et al.: Ultraviolet radiation-induced immunosuppression is greater in men and prevented by topical nicotinamide. J. Invest. Dermatol. 128, 447–454 (2008)

    CAS  PubMed  Google Scholar 

  70. Bouros, D., Zeros, G., Panaretos, C., et al.: Palpation vs pen method for the measurement of skin tuberculin reaction (Mantoux test). Chest 99, 416–419 (1991)

    Article  CAS  PubMed  Google Scholar 

  71. Damian, D.L., Halliday, G.M., Taylor, C.A., et al.: Ultraviolet radiation induced suppression of Mantoux reactions in humans. J. Invest. Dermatol. 110, 824–827 (1998)

    Article  CAS  PubMed  Google Scholar 

  72. Sivapirabu, G., Yiasemides, E., Halliday, G.M., Park, J., Damian, D.L.: Topical nicotinamide modulates cellular energy metabolism and provides broad-spectrum protection against ultraviolet radiation-induced immunosuppression in humans. British Journal of Dermatology 161, 1357–1364 (2009)

    Google Scholar 

  73. Bissett, D.L., Oblong, J.E., Berge, C.A.: Niacinamide: A B vitamin that improves aging facial skin appearance. Dermatol. Surg. 31, 860–865 (2005)

    Article  CAS  PubMed  Google Scholar 

  74. Kawada, A., Konishi, N., Oiso, N., et al.: Evaluation of anti-wrinkle effects of a novel cosmetic containing niacinamide. J. Dermatol. 35, 637–642 (2008)

    Article  CAS  PubMed  Google Scholar 

  75. Hazozaki, T., Minwalla, L., Zhuang, J., et al.: The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br. J. Dermatol. 147, 20–31 (2002)

    Article  Google Scholar 

  76. Ungerstedt, J.S., Blomback, M., Soderstrom, T.: Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin. Exp. Immunol. 131, 48–52 (2003)

    Article  CAS  PubMed  Google Scholar 

  77. Hedman, M., Ludvigsson, J., Faresjo, M.K.: Nicotinamide reduces high secretion of IFN-gamma in high-risk relatives even though it does not prevent type 1 diabetes. J. Interferon Cytokine Res. 26, 207–213 (2006)

    Article  CAS  PubMed  Google Scholar 

  78. Bogan, K.L., Brenner, C.: Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition. Annu. Rev. Nutr. 28, 115–130 (2008)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dermatology, Gloucester House Level 3, University of Sydney at Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia

    Diona L. Damian

  2. Dermatology Laboratories Blackburn Building D06, University of Sydney, Sydney, NSW, 2006, Australia

    Gary M. Halliday

Authors
  1. Diona L. Damian
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gary M. Halliday
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Diona L. Damian .

Editor information

Editors and Affiliations

  1. Inst. Umweltmedizinische Forschung (IUF), Universität Düsseldorf, Auf'm Hennekamp 50, Düsseldorf, 40225, Germany

    Jean Krutmann

  2. Service Dermatologie et, Medecine Vasculaire, CHU Besancon, place Saint-Jacques 2, Besancon, 25030, France

    Philippe Humbert

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Damian, D.L., Halliday, G.M. (2010). Photoprotection by Nicotinamide. In: Krutmann, J., Humbert, P. (eds) Nutrition for Healthy Skin. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-12264-4_11

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-12264-4_11

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-12263-7

  • Online ISBN: 978-3-642-12264-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation